

INC Research Holdings, Inc.

First Look at Strong Fourth-Quarter Results; 2015 Guidance Modestly Better Than Consensus

- Quarterly result overview. INC reported strong fourth-quarter results on Tuesday morning, February 24—the company's first earnings release since its initial public offering. EPS exceeded our target by 7 cents on better revenues and an EBITDA margin 141 basis points above our target. We note that the adjusted EPS total of \$0.26 reported by the company excludes stock compensation expenses, and thus enhances the quarter's performance by roughly 1 cent. Relative to our model, better revenue (more than 1 cent) and gross margin (5 cents) drove the outperformance, with items below the operating line adding 1 cent. Full-year operating margin gains were also impressive, increasing nearly 280 basis points from a year ago, but 111 basis points of this improvement can be attributed to \$9 million (111 basis points of margin) of extra charge orders filled in the second and third quarter. We do not believe unusual change order activity affected the fourth-quarter results.
- **Bookings were \$70 million better.** Net new business was \$316.7 million, producing a book-to-bill ratio of 1.48 times. We had modeled \$246.9 million in bookings and a book-to-bill ratio of 1.20 times. The better awards total extends the trend of strong bookings delivered by clinical CROs so far this quarter. This level of bookings should support management's expectation for low-double-digit revenue growth in 2015. We look for additional detail on the mix of the new wins on Tuesday's 7:00 a.m. conference call.
- Guidance for 2015 appears modestly better than consensus. Guidance for calendar 2015 was introduced, calling for revenues of \$870 million to \$900 million, which implies a respectable 7.4% to 11.1% increase despite several points of currency-related headwind. Management's target is \$10 million above our estimate at the midpoint, and brackets the consensus of \$881 million (see exhibit 2, on page 2).

Adjusted EPS guidance calls for a range of \$1.19 to \$1.29 (up 42% to 55%). The midpoint of the range is 11 cents above our \$1.13 target (excluding 4 cents of stock compensation expense) and 4 cents above consensus.

• Valuation and stock thoughts. As of Monday's close, INC trades at 23.0 times our current 2015 EPS estimate of \$1.13 (up 21.1%). Currently, the clinical CRO peer group trades at 21.0 times (ICON [ICLR \$61.94; Outperform] at 19.7 times, Quintiles [Q \$46.99; Outperform] at 21.2 times, PRA Health Sciences [PRAH \$28.65; Outperform] at 21.1 times, and Parexel [PRXL \$64.75; Outperform] at 22.1 times). We believe these results are modestly above expectations despite the notable currency headwind. We are constructive on the CRO group and maintain our Outperform rating on INC given the company's industry leading growth profile. We will update our model following Tuesday's earnings call, and expect to increase our overall 2015 EPS estimates by 10 to 12 cents. Exhibits 1 and 3, on the following pages, break down the fourth quarter versus our expectations.

INC Research is one of the top 10 largest CROs, with an annual revenue base exceeding \$800 million. Founded in 1985 as a niche CRO focused on central nervous system disorders, INC now employs 5,400 associates across 50 countries, and its focus has broadened to include oncology and other complex diseases.

John Kreger +1 312 364 8597 jkreger@williamblair.com **Roberto Fatta** +1 312 364 8797 rfatta@williamblair.com Matt Bacso, CFA +1 312 364 8996 mbacso@williamblair.com February 24, 2015

Stock Rating: **Outperform**Company Profile: **Aggressive Growth**


Symbol: INCR (NASDAQ)
Price: \$25.99 (52-Wk.: \$20-\$29)
Market Value (mil.): \$1,560
Fiscal Year End: December
Long-Term EPS Growth Rate: 20%
Dividend/Yield: None

		2013A	2014E	2015E
Estimates				
EPS	Q1	\$-0.03	A\$0.14	NA
	Q2	\$0.06	A\$0.26	NA
	Q3	\$0.16	A\$0.35	NA
	Q4	\$0.10	\$0.19	NA
	FY	\$0.30	\$0.93	\$1.13
	CY		\$0.93	\$1.13
Valu	ation			
FY P	/E	86.6x	27.9x	23.0x
CY P	/E		27.9x	23.0x

Trading Data (FactSet)	
Shares Outstanding (mil.)	60
Float (mil.)	23
Average Daily Volume	213,333

Financial Data (FactSet)	
Long-Term Debt/Total Capital (MRQ)	0.0
Book Value Per Share (MRQ)	0.0
Return on Equity (TTM)	-14.2

Two-Year Price Performance Chart



Sources: FactSet, William Blair & Company estimates

Please consult pages 4-5 of this report for all disclosures. Analyst certification is on page 4. William Blair & Company, L.L.C. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as a single factor in making an investment decision.

Exhibit 1. Fourth-Quarter EPS Performance Relative to William Blair Estimates

Revenues	\$ 0.012
Gross Profit	\$ 0.037
Selling & Marketing	\$ (0.005)
Depreciation	\$ 0.015
Interest	\$ 0.005
Taxes	\$ -
Share Count	\$ 0.002
Total	\$ 0.066

Sources: Company reports and William Blair & Company, L.L.C. estimates

Exhibit 2. Current 2015 Guidance Relative to William Blair Estimates and Consensus

Revenue (\$M)
Growth
Adjusted EPS (excl. SBC)
Growth (decline)
Adjusted EPS (incl. SBC)
Growth (decline)

2015 Guidance	
\$870 to 900	
7.4% to 11.1%	
\$1.19 to \$1.29	
42% to 55%	
\$1.14 to \$1.24	
44% to 57%	

2015 Estimates				
WB - Prior to Call	Consensus - Prior to Call			
\$870	\$881			
8.5%	10.0%			
\$1.13	\$1.20			
21.1%	33.3%			
\$1.09	NA			
21.4%				

 $Sources: Company\ reports, FactSet, and\ William\ Blair\ \&\ Company, L.L.C.\ estimates$

Exhibit 3. Fourth Quarter 2014 EPS Variance Analysis

February 24, 2015	4Q 2014	4Q 2013	Year/Year	4Q 2014	Year/Year	ActEst.
	(Actual)	(Actual)	<u>% Change</u>	(Estimate)	% Change	<u>Difference</u>
Total Net Revenue	213,725	174,365	22.6%	205,745	18.0%	7,980
Direct Costs	133,957	112,080	19.5%	132,294	18.0%	1,663
Selling, general, and administrative (incl options)	40,494	34,012	<u>19.1%</u>	38,474	<u>13.1%</u>	<u>2,020</u>
Stock-based comp expense	<u>(1,065)</u>	<u>(1,566)</u>	<u>-32.0%</u>	<u>(960)</u>	<u>-38.7%</u>	<u>(105)</u>
Total operating expenses	173,386	144,526	20.0%	169,808	17.5%	3,578
EBITDA (excluding SBC)	40,339	29,839	35.2%	35,937	20.4%	4,402
Depreciation	4,991	5,241	-4.8%	6,172	17.8%	(1,181)
Operating income (excluding SBC)	35,348	24,598	43.7%	29,765	21.0%	5,583
Interest and other income (expense)	(11,160)	(16,344)	-31.7%	(11,600)	-29.0%	440
Earnings before tax	24,188	8,254	193.0%	18,165	120.1%	6,023
Income taxes (expense) benefit	(8,950)	(3,054)	193.1%	(6,721)	120.1%	(2,229)
Adjusted net income (excluding SBC)	15,238	5,200	193%	11,444	120.1%	3,794
Shares outstanding	58,788	52,003	13.0%	59,189	13.8%	(401)
EPS (excluding SBC)	\$0.26	\$0.10	159%	\$0.19	93.4%	0.07
EPS (including SBC)	\$0.25	\$0.08	206%	\$0.18	126.0%	0.06
% of Net Revenue:			<u>Change</u>		<u>Difference</u>	
Gross profit	37.32	35.72	1.60	35.70	(0.02)	1.62
Selling, general and administrative	18.95	19.51	(0.56)	18.70	(0.81)	0.25
Stock-based comp expense	0.50	0.90	(0.40)	0.47	(0.43)	0.03
EBITDA	18.87	17.11	1.76	17.47	0.35	1.41
Depreciation	2.34	3.01	(0.67)	3.00	(0.01)	(0.66)
EBITA	16.54	14.11	2.43	14.47	0.36	2.07
Tax rate	37.00	37.00	0.00	37.00	(0.00)	0.00
Net Income	7.13	2.98	4.15	5.56	2.58	1.57
Bookings				J		
Net new business	316,700	285,200	31,500	246,894	(38,306)	69,806
Net Book-to-Bill	1.48	1.64		1.20		

Sources: Company reports, FactSet, and William Blair & Company, L.L.C. estimates

IMPORTANT DISCLOSURES

William Blair was a manager or co-manager of a public offering of equity securities for INC Research Holdings, Inc. within the prior 12 months.

William Blair is a market maker in the security of INC Research Holdings, Inc.

William Blair intends to seek investment banking compensation in the next three months from INC Research Holdings, Inc.

Within the past 12 months William Blair has provided or is providing investment banking services to or has an investment services relationship with INC Research Holdings, Inc.


Additional information is available upon request.

This report is available in electronic form to registered users via R*Docs™ at www.rdocs.com or www.williamblair.com.

Please contact us at +1 800 621 0687 or consult williamblair.com/Research-and-Insights/Equity-Research/Coverage.aspx for all disclosures.

John Kreger attests that 1) all of the views expressed in this research report accurately reflect his/her personal views about any and all of the securities and companies covered by this report, and 2) no part of his/her compensation was, is, or will be related, directly or indirectly, to the specific recommendations or views expressed by him/her in this report. We seek to update our research as appropriate, but various regulations may prohibit us from doing so. Other than certain periodical industry reports, the majority of reports are published at irregular intervals as deemed appropriate by the analyst.

DOW JONES: 18,116.84 S&P 500: 2,109.66 NASDAQ: 4,960.97



Current Rating Distribution (as of 01/31/15)

Coverage Universe	Percent	Inv. Banking Relationships*	Percent	
Outperform (Buy)	64	Outperform (Buy)	16	
Market Perform (Hold)	32	Market Perform (Hold)	2	
Underperform (Sell)	2	Underperform (Sell)	0	

^{*}Percentage of companies in each rating category that are investment banking clients, defined as companies for which William Blair has received compensation for investment banking services within the past 12 months.

The compensation of the research analyst is based on a variety of factors, including performance of his or her stock recommendations; contributions to all of the firm's departments, including asset management, corporate finance, institutional sales, and retail brokerage; firm profitability; and competitive factors.

OTHER IMPORTANT DISCLOSURES

Stock ratings, price targets, and valuation methodologies: William Blair & Company, L.L.C. uses a three-point system to rate stocks. Individual ratings and price targets (where used) reflect the expected performance of the stock relative to the broader market (generally the S&P 500, unless otherwise indicated) over the next 12 months. The assessment of expected performance is a function of near-, intermediate-, and long-term company fundamentals, industry outlook, confidence in earnings estimates, valuation (and our valuation methodology), and other factors. Outperform (O) – stock expected to outperform the broader market over the next 12 months; Market Perform (M) – stock expected to perform approximately in line with the broader market over the next 12 months; Underperform (U) – stock expected to underperform the broader market over the next 12 months; not rated (NR) – the stock is not currently rated. The valuation methodologies used to determine price targets (where used) include (but are not limited to) price-to-earnings multiple (P/E), relative P/E (compared with the relevant market), P/E-to-growth-rate (PEG) ratio, market capitalization/revenue multiple, enterprise value/EBITDA ratio, discounted cash flow, and others.

Company Profile: The William Blair research philosophy is focused on quality growth companies. Growth companies by their nature tend to be more volatile than the overall stock market. Company profile is a fundamental assessment, over a longer-term horizon, of the business risk of the company relative to the broader William Blair universe. Factors assessed include: 1) durability and strength of franchise (management strength and track record, market leadership, distinctive capabilities); 2) financial profile (earnings growth rate/consistency, cash flow generation, return on investment, balance sheet, accounting); 3) other factors such as sector or industry conditions, economic environment, confidence in long-term growth prospects, etc. Established Growth (E) – Fundamental risk is lower relative to the broader William Blair universe; Core Growth (C) – Fundamental risk is approximately in line with the broader William Blair universe; Aggressive Growth (A) – Fundamental risk is higher relative to the broader William Blair universe.

The ratings, price targets (where used), valuation methodologies, and company profile assessments reflect the opinion of the individual analyst and are subject to change at any time.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies—to our clients and our trading desks—that are contrary to opinions expressed in this research. Certain outstanding reports may contain discussions or investment opinions relating to securities, financial instruments and/or issuers that are no longer current. Always refer to the most recent report on a company or issuer before making an investment decision. Our asset management and trading desks may make investment decisions that are inconsistent with recommendations or views expressed in this report. We will from time to time have long or short positions in, act as principal in, and buy or sell the securities referred to in this report. Our research is disseminated primarily electronically, and in some instances in printed form. Electronic research is simultaneously available to all clients. This research is for our clients only. No part of this material may be copied or duplicated in any form by any means or redistributed without the prior written consent of William Blair & Company, L.L.C.

This is not in any sense a solicitation or offer of the purchase or sale of securities. The factual statements herein have been take from sources we believe to be reliable, but such statements are made without any representation as to accuracy or completeness or otherwise. Opinions expressed are our own unless otherwise stated. Prices shown are approximate.

This material is distributed in the United Kingdom and the European Economic Area (EEA) by William Blair International, Ltd., authorized and regulated by the Financial Conduct Authority (FCA), and is only directed at and is only made available to persons falling within articles 19, 38, 47, and 49 of the Financial Services and Markets Act of 2000 (Financial Promotion) Order 2005 (all such persons being referred to as "relevant persons"). This document is intended for persons regarded as professional investors (or equivalent) and is not to be distributed to or passed onto any "retail clients." No persons other than persons to whom this document is directed should rely on it or its contents or use it as the basis to make an investment decision.

"William Blair" and "R*Docs" are registered trademarks of William Blair & Company, L.L.C. Copyright 2015, William Blair & Company, L.L.C. All rights reserved.